ArticleExperimental and therapeutic medicine2025
Adenosine A1 receptor agonist alleviates cerebral ischemia/reperfusion injury by inhibiting Nrf2/NLRP3 signaling‑mediated pyroptosis.
Article in Experimental and therapeutic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ADSC-derived exosomes inhibit myofibroblast transdifferentiation and attenuate airway stenosis via METTL3-mediated m6A modification of TLR2.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to investigate whether adenosine A1 receptor (A1R) agonists can alleviate cerebral ischemia/reperfusion (I/R) injury by inhibiting pyroptosis mediated through the nuclear factor erythroid 2-related factor 2 (Nrf2)/NLR family pyrin domain containing 3 (NLRP3) signaling pathway. A total of 36 Sprague-Dawley rats were randomly assigned to the following four groups: Sham (sham group), I/R (model group), adenosine A1 receptor agonist preconditioning [model + adenosine A1R agonist 2-chloro-N(6)-cyclopentyladenosine] group and ML385 (model + adenosine A1R agonist group + Nrf2 pathway inhibitor group). A middle cerebral artery occlusion model was induced using the thread occlusion method. Neurological function was assessed using the Longa scale, brain infarction volume was determined through 2,3,5-triphenyltetrazolium chloride staining, protein expression of Nrf2, NLRP3, caspase-1, GSDMD and IL-1β was assessed using western blotting, and the expression of Nrf2 and GSDMD was assessed using immunofluorescence. The findings revealed that adenosine A1R agonist improved neurological function and reduced infarct size. Mechanistically, this was found to be associated with the activation of the Nrf2/NLRP3 signaling pathway and the suppression of pyroptosis-associated proteins (gasdermin D, caspase-1 and IL-1β) expression. Notably, the Nrf2 inhibitor ML385 reversed the aforementioned effects induced by the adenosine A1R agonist. These results suggest that adenosine A1R agonist can alleviate cerebral I/R injury in rats, potentially by modulating the Nrf2/NLRP3 signaling pathway to inhibit pyroptosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.